JP6964593B2 - ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン - Google Patents

ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Download PDF

Info

Publication number
JP6964593B2
JP6964593B2 JP2018540013A JP2018540013A JP6964593B2 JP 6964593 B2 JP6964593 B2 JP 6964593B2 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 6964593 B2 JP6964593 B2 JP 6964593B2
Authority
JP
Japan
Prior art keywords
treatment
administered
day
compound
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018540013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507134A (ja
JP2019507134A5 (enExample
Inventor
アラン エフ． リスト，
デイビッド エー． サルマン，
ジョン エス． コバック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019507134A publication Critical patent/JP2019507134A/ja
Publication of JP2019507134A5 publication Critical patent/JP2019507134A5/ja
Application granted granted Critical
Publication of JP6964593B2 publication Critical patent/JP6964593B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018540013A 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Expired - Fee Related JP6964593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287858P 2016-01-27 2016-01-27
US62/287,858 2016-01-27
PCT/US2017/015237 WO2017132445A1 (en) 2016-01-27 2017-01-27 Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor

Publications (3)

Publication Number Publication Date
JP2019507134A JP2019507134A (ja) 2019-03-14
JP2019507134A5 JP2019507134A5 (enExample) 2020-03-12
JP6964593B2 true JP6964593B2 (ja) 2021-11-10

Family

ID=59398691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540013A Expired - Fee Related JP6964593B2 (ja) 2016-01-27 2017-01-27 ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン

Country Status (6)

Country Link
US (2) US20190111053A1 (enExample)
EP (1) EP3407887B1 (enExample)
JP (1) JP6964593B2 (enExample)
CN (1) CN109475543A (enExample)
CA (1) CA3051828A1 (enExample)
WO (1) WO2017132445A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
JP7187023B6 (ja) 2015-05-15 2023-01-05 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンプロドラッグ
US20190240290A1 (en) * 2016-08-04 2019-08-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Companion diagnostic for combination lenalidomide and erythropoietin treatment
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030617A2 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer therapy with cantharidin and cantharidin analogs
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
KR20160004299A (ko) * 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
WO2016014778A1 (en) * 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US20160074390A1 (en) * 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor

Also Published As

Publication number Publication date
CN109475543A (zh) 2019-03-15
EP3407887B1 (en) 2021-09-01
US20190111053A1 (en) 2019-04-18
WO2017132445A1 (en) 2017-08-03
US20220323433A2 (en) 2022-10-13
CA3051828A1 (en) 2017-08-03
JP2019507134A (ja) 2019-03-14
EP3407887A1 (en) 2018-12-05
EP3407887A4 (en) 2019-09-25
WO2017132445A8 (en) 2018-12-20
US20220184066A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US20220323433A2 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
EP3349759B1 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
KR102613106B1 (ko) Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
Bi et al. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage
JP7285001B2 (ja) サフラナール製剤による肝臓癌治療の方法
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CN113260361A (zh) 使用免疫调节治疗癌症的新型方法
EP4095137A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
HK40000014B (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
US11918550B2 (en) Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine
KR102595271B1 (ko) 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물
CA3217214A1 (en) Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
KR20260035261A (ko) 올루타시데닙, 베네토클락스 및 저메틸화제를 사용한 급성 골수성 백혈병의 치료
TW202608449A (zh) 替拉紮明（ｔｉｒａｐａｚａｍｉｎｅ）組合物及方法
WO2022175858A1 (en) Dicarboximide derivative for use in cancer treatment
WO2026101931A1 (en) Methods of treating myelodysplastic syndrome
HK40092504A (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害
HK40003387B (en) Therapeutic compositions for treating pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211019

R150 Certificate of patent or registration of utility model

Ref document number: 6964593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees